Does dipeptidyl peptidase-4 inhibitor anagliptin ameliorate diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet?
High-dose anagliptin treatment improved glucose tolerance by suppression of body weight gain and amelioration of insulin resistance, whereas low-dose anagliptin treatment improved glucose tolerance by enhancing insulin secretion.
Currently there is no strong evidence to support the use of any one intervention type. Future research should use combinations of approaches, as there is some evidence that these are more likely to be successful.